News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
108,624 Results
Type
Article (3263)
Company Profile (49)
Press Release (105312)
Multimedia
Podcasts (4)
Webinars (3)
Section
Business (33372)
Career Advice (202)
Deals (9895)
Drug Delivery (9)
Drug Development (10380)
Employer Resources (12)
FDA (1706)
Job Trends (2239)
News (55378)
Policy (3694)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (220)
Allergies (8)
Alliances (8891)
ALS (12)
Alzheimer's disease (179)
Antibody-drug conjugate (ADC) (20)
Approvals (1720)
Artificial intelligence (17)
Autoimmune disease (3)
Automation (3)
Bankruptcy (94)
Best Places to Work (1803)
BIOSECURE Act (2)
Biosimilars (18)
Biotechnology (35)
Bladder cancer (10)
Brain cancer (6)
Breast cancer (38)
Cancer (335)
Cardiovascular disease (11)
Career advice (171)
Career pathing (1)
CAR-T (22)
Cell therapy (70)
Cervical cancer (3)
Clinical research (8506)
Collaboration (144)
Compensation (73)
COVID-19 (259)
CRISPR (7)
C-suite (47)
Cystic fibrosis (12)
Data (307)
Denatured (3)
Depression (6)
Diabetes (29)
Diagnostics (1085)
Digital health (4)
Diversity, equity & inclusion (2)
Drug discovery (21)
Drug pricing (9)
Duchenne muscular dystrophy (15)
Earnings (11113)
Editorial (3)
Employer branding (2)
Employer resources (10)
Events (15650)
Executive appointments (185)
FDA (1866)
Featured Employer (7)
Frontotemporal dementia (1)
Funding (158)
Gene editing (17)
Gene therapy (27)
GLP-1 (83)
Government (321)
Guidances (4)
Healthcare (2616)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (19)
Indications (4)
Infectious disease (274)
Inflammatory bowel disease (26)
Inflation Reduction Act (6)
Influenza (9)
Intellectual property (19)
Interviews (29)
IPO (5558)
IRA (7)
Job creations (477)
Job search strategy (152)
Kidney cancer (4)
Labor market (4)
Layoffs (45)
Leadership (1)
Legal (1082)
Liver cancer (8)
Lung cancer (49)
Lymphoma (14)
Management (4)
Manufacturing (33)
MASH (10)
Medical device (2072)
Medtech (2072)
Mergers & acquisitions (4633)
Metabolic disorders (75)
Multiple sclerosis (14)
NASH (1)
Neurodegenerative disease (11)
Neuropsychiatric disorders (3)
Neuroscience (270)
NextGen: Class of 2025 (1204)
Non-profit (306)
Northern California (574)
Now hiring (4)
Obesity (33)
Opinion (17)
Ovarian cancer (16)
Pain (17)
Pancreatic cancer (19)
Parkinson's disease (23)
Partnered (5)
Patents (55)
Patient recruitment (15)
Peanut (3)
People (11408)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (3003)
Phase II (4040)
Phase III (2610)
Pipeline (213)
Policy (13)
Postmarket research (175)
Preclinical (1216)
Press Release (3)
Prostate cancer (10)
Psychedelics (3)
Radiopharmaceuticals (53)
Rare diseases (48)
Real estate (905)
Recruiting (6)
Regulatory (2560)
Reports (9)
Research institute (274)
Resumes & cover letters (23)
RSV (3)
Schizophrenia (20)
Series A (30)
Series B (11)
Service/supplier (2)
Sickle cell disease (9)
Southern California (602)
Special edition (1)
Spinal muscular atrophy (4)
Sponsored (1)
Startups (921)
State (1)
Stomach cancer (2)
Supply chain (10)
The Weekly (1)
United States (4576)
Vaccines (50)
Venture capitalists (8)
Weight loss (14)
Women's health (1)
Worklife (1)
Date
Last 7 days (109)
Last 30 days (419)
Last 365 days (6149)
2025 (1801)
2024 (6739)
2023 (7983)
2022 (9887)
2021 (11208)
2020 (10432)
2019 (7051)
2018 (5427)
2017 (5471)
2016 (4643)
2015 (6094)
2014 (4291)
2013 (3544)
2012 (3897)
2011 (3556)
2010 (3167)
Location
Africa (62)
Alabama (3)
Arizona (36)
Arkansas (1)
Asia (5415)
Australia (739)
California (1450)
Canada (264)
China (68)
Colorado (41)
Connecticut (54)
Delaware (15)
Europe (8748)
Florida (178)
Georgia (28)
Idaho (10)
Illinois (67)
India (2)
Indiana (85)
Japan (16)
Kansas (28)
Kentucky (1)
Maine (35)
Maryland (119)
Massachusetts (723)
Michigan (69)
Minnesota (55)
Mississippi (2)
Missouri (14)
Montana (2)
Nebraska (4)
Nevada (25)
New Hampshire (9)
New Jersey (321)
New Mexico (2)
New York (328)
North Carolina (271)
Northern California (574)
Ohio (53)
Oklahoma (2)
Oregon (7)
Pennsylvania (229)
Rhode Island (4)
South America (99)
South Carolina (7)
Southern California (602)
Tennessee (24)
Texas (224)
Utah (43)
Virginia (30)
Washington D.C. (2)
Washington State (101)
West Virginia (1)
Wisconsin (16)
108,624 Results for "kashiv biosciences llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
February 26, 2025
·
2 min read
Press Releases
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
April 7, 2025
·
2 min read
Press Releases
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.
July 1, 2024
·
7 min read
Press Releases
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
January 29, 2025
·
1 min read
Press Releases
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
November 4, 2024
·
2 min read
Drug Development
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has enrolled the first patient in its Phase III clinical study involving ADL018, the Company’s biosimilar candidate to XOLAIR®.
October 2, 2023
·
3 min read
Pharm Country
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Alvotech and Kashiv Biosciences LLC announced that they have entered into an exclusive licensing agreement for AVT23, a proposed biosimilar to Xolair®, which is currently in clinical development.
October 3, 2023
·
8 min read
Business
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Kashiv Biosciences LLC today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development.
October 3, 2023
·
9 min read
Drug Development
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
Kashiv Biosciences, LLC announced that ADL018, a biosimilar candidate to Xolair®, completed a successful global Phase 1 clinical study in healthy volunteers.
July 5, 2023
·
3 min read
Press Releases
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
April 3, 2025
·
4 min read
1 of 10,863
Next
